|
|
Post by otherottawaguy on Jan 21, 2020 11:51:43 GMT -5
(let's stay on topic this time)
Is this the effects of the expiration on Friday and pent up demand caused by MLK Day?
|
|
|
|
Post by LongMNKD on Jan 21, 2020 11:57:17 GMT -5
AAPL buyout offer coming
|
|
|
|
Post by casualinvestor on Jan 21, 2020 11:58:27 GMT -5
With plenty of observer bias and hopium:
A run-up before the UTHR presentation that's bigger than any of us would expect. Nothing announced. And after that, a drop and plenty of short volume. Now, a week later a bigger run-up with no news and no conference.
Is there a shoe waiting to drop? Possibly an old one, with plenty of holes, leaking like a sieve.
|
|
|
|
Post by awesomo on Jan 21, 2020 11:59:55 GMT -5
One of life's unanswerable mysteries, so I'm gonna go with...  |
|
|
|
Post by sportsrancho on Jan 21, 2020 12:04:19 GMT -5
Might be just what Nate said.
|
|
|
|
Post by brotherm1 on Jan 21, 2020 12:10:30 GMT -5
Retail investors from Brazil and over the 200 day avg. and second molecule; and agreement to sell Afrezza in Canada.
|
|
|
|
Post by jlaw277 on Jan 21, 2020 12:13:09 GMT -5
Starting to think the appointment of Hooper to the board is a meaningful event, even if just a confirmation of the company's potential. Hooper was a major player at Amgen and at BMY before that. He was the second highest compensated executive at Amgen for multiple years, second only to the CEO. Needless to say, the guy will be careful with his reputation and his legacy. See here: www.sec.gov/Archives/edgar/data/318154/000119312519100704/d629495ddef14a.htm (page 67) His willingness to be on the board is a signal of some sort that might be meaningful to larger institutional investors looking for some industry affirmation. It could be this plus Brazil sales plus what Nate referenced regarding LEAP expiration. Also from the above referenced proxy: Anthony Hooper retired from the role of Executive Vice President, Global Commercial Operations on September 3, 2018, after serving in this role since 2011. Murdo Gordon joined us as our Executive Vice President, Global Commercial Operations, effective September 3, 2018, from Bristol-Myers Squibb Company where he served as Chief Commercial Officer since 2016 and, prior to that, head of worldwide markets. Mr. Hooper continues to be employed in a non-executive officer capacity to assist in the transition, as well as to lead and execute on several corporate strategic objectives.
|
|
|
|
Post by lennymnkd on Jan 21, 2020 12:20:41 GMT -5
I don't know who to give a thumbs up too !! I'm so confused 😜
|
|
|
|
Post by louaboardalia on Jan 21, 2020 12:33:21 GMT -5
|
|
|
|
Post by myocat on Jan 21, 2020 12:37:33 GMT -5
maybe, "MannKind's Afrezza Reveals Veins Of Gold" from Kastanes did some good
|
|
|
|
Post by peppy on Jan 21, 2020 12:38:41 GMT -5
maybe, "MannKind's Afrezza Reveals Veins Of Gold" from Kastanes did some good that is not the reason. |
|
|
|
Post by porkini on Jan 21, 2020 12:57:58 GMT -5
maybe, "MannKind's Afrezza Reveals Veins Of Gold" from Kastanes did some good that is not the reason. Still - made me laugh!  |
|
|
|
Post by wgreystone on Jan 21, 2020 12:59:54 GMT -5
MNKD tends to rally at least once per year.
|
|
|
|
Post by kc on Jan 21, 2020 13:00:01 GMT -5
Mike drove by the Amgen HQ over the weekend. Drive By......
|
|
|
|
Post by Clement on Jan 21, 2020 13:02:41 GMT -5
Starting to think the appointment of Hooper to the board is a meaningful event, even if just a confirmation of the company's potential. Hooper was a major player at Amgen and at BMY before that. He was the second highest compensated executive at Amgen for multiple years, second only to the CEO. Needless to say, the guy will be careful with his reputation and his legacy. See here: www.sec.gov/Archives/edgar/data/318154/000119312519100704/d629495ddef14a.htm (page 67) His willingness to be on the board is a signal of some sort that might be meaningful to larger institutional investors looking for some industry affirmation. It could be this plus Brazil sales plus what Nate referenced regarding LEAP expiration. Also from the above referenced proxy: Anthony Hooper retired from the role of Executive Vice President, Global Commercial Operations on September 3, 2018, after serving in this role since 2011. Murdo Gordon joined us as our Executive Vice President, Global Commercial Operations, effective September 3, 2018, from Bristol-Myers Squibb Company where he served as Chief Commercial Officer since 2016 and, prior to that, head of worldwide markets. Mr. Hooper continues to be employed in a non-executive officer capacity to assist in the transition, as well as to lead and execute on several corporate strategic objectives.
Market cap of Beigene is 13 B. On Jan 2 Beigene announced a deal with Amgen. And the same day they announced Hooper on their board. In a previous thread (Nate on Twitter, Jan 17), Jlaw posted, "Looks like the appointment of Hooper to the BeiGene board was an agreed upon part of the Amgen deal, which means he serves more or less as a representative of Amgen's interests even though he is an independent director. Maybe his retirement made him more useful in this way, as he could be deployed as "independent." See the 8-k from 10.31.19: "As part of the Share Purchase Agreement, Amgen will receive the right to designate an independent director to serve on BeiGene’s board of directors." Item 1.01end of 2nd paragraph: 10.31.19 AMGN 8-k Remains interesting that he is one of our board members." Read more: mnkd.proboards.com/search/results?captcha_id=captcha_search&what_at_least_one=beigene&who_only_made_by=0&display_as=0&search=Search#ixzz6Bgn2GmGB |
|
